Shares of Medtronic closed down a modest 1.89% on Monday with nearly 10.5 million shares traded. The stock was one of the most active stocks on the NYSE. A federal court has barred Medtronic Inc. from selling its new artificial heart valve to most patients in the U.S., despite finding that the device is "safer" and has "a lower risk of death" than a competing device.

Shares of Himax Technologies closed down about 14% on Monday with around 21.8 million shares traded. There was no news to explain the fall but earlier this month The Street gave the stock a buy rating. "We rate HIMAX TECHNOLOGIES INC (HIMX) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow."

Shares of CHDX closed up nearly 16% on Monday with almost a million shares traded. The stock was one of the biggest gainers on the NASDAQ. The pop came after it was announced that the company received a cash offer from a bidder for all of the company's outstanding common stock shares at $23 per share. Chindex’s "Transaction Committee" deemed the offer a "superior proposal" to a previous bid by a buyer consortium. The previous group had offered $19.50 in cash per outstanding share.

Fortitude Group closed down 33.44% with about 46 million shares traded on Monday. The company was one of the biggest decliners in the OTC marketplace. Last week the company submitted the certificate to the Affinity transfer agent to have the shares re-issued and forwarded to bona fide Fortitude shareholders of record, as of the calendar date: March 14, 2014 at 6:00pm EDT.

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.